Maximum quantity allowed is 999
请选择数量
CAS RN: 17902-23-7 | 产品编码: F0635
5-Fluoro-1-(tetrahydro-2-furfuryl)uracil
×
![]()
×
技术规格
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(with Total Nitrogen) | min. 98.0 % |
| Melting point | 167.0 to 171.0 °C |
| NMR | confirm to structure |
物性（参考值）
| 熔点 | 169 °C |
GHS
| 象形图 |
|
| 信号词 | Danger |
| 危险性说明 | H300 : Fatal if swallowed. H373 : May cause damage to organs through prolonged or repeated exposure. |
| 防范说明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P314 : Get medical advice/ attention if you feel unwell. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
相关法规
| RTECS# | YR0450000 |
运输信息
| UN编号 | UN2811 |
| 类别 | 6.1 |
| 包装类别 | II |
| HS编码* | 2940.00-000 |
应用
Tegafur: A Prodrug of an Active Antitumor 5-FU
Tegafur is a prodrug that is metabolized by cytochrome P 450 to an active antitumor 5-FU [F0151]. Tegafur is often used as combined agents such as UFT (tegafur and uracil [U0013] at a molar ratio of 1:4) or S-1 (tegafur, gimeracil [C2243] and potassium oxonate [O0164] at a molar ratio of 1:0.4:1) to increase the plasma and tumor 5-FU concentrations. Determination of the combined agents in plasma is important to evaluate the safety and efficacy of them. (The product is for research purpose only.)
References
- Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents
- Bioactivation of Tegafur to 5-fluorouracil is catalyzed by cytochrome P 450 2A6 in human liver microsomes in vitro
- Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes
- Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
- Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review
- Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry
- Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry
参考文献
文章/手册
TCIMail
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。